{"entity":{"id":"nct05490472","kind":"trial","name":"JAB-2485 Activity in Adult Patients With Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of JAB-2485 (Aurora A inhibitor) in triple-negative breast cancer and small-cell lung cancer, run by Jacobio Pharmaceuticals Co., Ltd., now recruiting.","summary":"JAB-2485 Activity in Adult Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05490472 by Jacobio Pharmaceuticals Co., Ltd., with 102 participants planned, started 2022-12-20 and due to reach its primary completion in 2026-08. Interventions recorded: JAB-2485 (Aurora A inhibitor).","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05490472","url":"https://clinicaltrials.gov/study/NCT05490472"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["tnbc","sclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05490472","phase":"1/2","setting":"A Phase 1/2a, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-2485 in Adult Patients With Advanced Solid Tumors","sponsor":"Jacobio Pharmaceuticals Co., Ltd.","enrolled":102,"outcomes":[]},"route":"/trials/nct05490472/","neighbours":{"cancer":[{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"company":[{"id":"jacobio-pharmaceuticals","kind":"company","name":"Jacobio Pharmaceuticals","route":"/companies/jacobio-pharmaceuticals/"}]}}